Brussels, Belgium: European Organisation for Research and Treatment of Cancer (EORTC) and European Society for Radiotherapy and Oncology (ESTRO) announces the first site activation for the E²-RADIatE platform.
E²-RADIatE is a platform built to host prospective data registries of “real-world” data on patients treated with radiotherapy. Radiation therapy still suffers from a lack of collective knowledge on how treatments affect patient’s survival and quality of life. For a number of cancers and indications, information is available through clinical trials but formal data collection and data sharing is rather random especially with new treatments and techniques, possibly resulting in patients not receiving the best treatment for their cancer.
The platform will link diagnostic, radiation imaging, and treatment data to clinical outcomes for a number of cancers, thereby facilitating the analysis of new clinical indications treated with radiotherapy and the monitoring of new radiation techniques and technologies.
“This joint development of a holistic database and infrastructure for radiation oncology research is in line with the ESTRO Vision 2030,” says Professor Yolande Lievens, ESTRO Past-President and E²-RADIatE Study Coordinator.
OligoCare is the first project hosted on the E²-RADIatE platform that will collect data on the treatment of oligometastatic disease in lung, breast, prostate and colorectal cancer. The objective of this data collection is to identify what factors (cancer, organ affected, staging, treatment) have an impact on overall survival of patients who develop oligometastatic disease at some point.